Kopran Limited — JV/Acquisition, 27-02-2026: Amalgamation/Merger

Kopran Ltd. has received a 'no adverse observations' letter from BSE for its proposed merger by absorption of Kopran Laboratories Ltd. into itself. This marks a significant step forward for the amalgamation, which aims for business synergies. While progressing, the scheme is still subject to further regulatory and judicial approvals, including from the NCLT. Kopran Ltd. will need to disclose the rationale, impact on shareholder value, and changes in shareholding patterns post-merger. The company must file the scheme with NCLT within six months of receiving the BSE observation letter.